Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma.
Talluri S, Samur MK, Buon L, Kumar S, Potluri LB, Shi J, Prabhala RH, Shammas MA, Munshi NC.
Blood Cancer J. 2021 Oct 08. 11(10):166. PMID: 34625538
Links
Bibliography
Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma.
Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, Garrido V, Rufian L, Sanchez R, Aguilar-Garrido P, Barrio S, Martín MA, Bolli N, Tai YT, Szalat R, Fulciniti M, Munshi N, Martínez-López J, Linares M, Gallardo M.
Cancers (Basel). 2021 Jun 25. 13(13). PMID: 34202390
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment.
Liu J, Hideshima T, Xing L, Wang S, Zhou W, Samur MK, Sewastianik T, Ogiya D, An G, Gao S, Yang L, Ji T, Bianchi G, Wen K, Tai YT, Munshi N, Richardson P, Carrasco R, Cang Y, Anderson KC.
Sci Adv. 2021 Jun. 7(23). PMID: 34088671
Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma.
Kumar S, Buon L, Talluri S, Roncador M, Liao C, Zhao J, Shi J, Chakraborty C, Gonzalez G, Tai YT, Prabhala R, Samur MK, Munshi NC, Shammas MA.
Commun Biol. 2021 05 24. 4(1):617. PMID: 34031527
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC.
Blood Cancer Discov. 2021 Sep. 2(5):468-483. PMID: 34568832
Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.
Ohguchi H, Park PMC, Wang T, Gryder BE, Ogiya D, Kurata K, Zhang X, Li D, Pei C, Masuda T, Johansson C, Wimalasena VK, Kim Y, Hino S, Usuki S, Kawano Y, Samur MK, Tai YT, Munshi NC, Matsuoka M, Ohtsuki S, Nakao M, Minami T, Lauberth S, Khan J, Oppermann U, Durbin AD, Anderson KC, Hideshima T, Qi J.
Blood Cancer Discov. 2021 07. 2(4):370-387. PMID: 34258103
miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.
Sewastianik T, Straubhaar JR, Zhao JJ, Samur MK, Adler K, Tanton HE, Shanmugam V, Nadeem O, Dennis PS, Pillai V, Wang J, Jiang M, Lin J, Huang Y, Brooks D, Bouxsein M, Dorfman DM, Pinkus GS, Robbiani DF, Ghobrial IM, Budnik B, Jarolim P, Munshi NC, Anderson KC, Carrasco RD.
Blood. 2021 04 08. 137(14):1905-1919. PMID: 33751108
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC.
Nat Commun. 2021 02 08. 12(1):868. PMID: 33558511
Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13.
Song Y, Du T, Ray A, Chauhan K, Samur M, Munshi N, Chauhan D, Anderson KC.
Blood Cancer J. 2021 01 13. 11(1):13. PMID: 33441535
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.
Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, García Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum C, Kumar S, Stadtmauer EA, Einsele H, Beksac M, Weisel K, Anderson KC, Mateos MV, Moreau P, San-Miguel J, Munshi NC, Avet-Loiseau H.
Blood. 2020 12 24. 136(26):3033-3040. PMID: 33367546